

Vijay Nambi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4424547/publications.pdf>

Version: 2024-02-01

159
papers

5,592
citations

109321

35
h-index

85541

71
g-index

160
all docs

160
docs citations

160
times ranked

7934
citing authors

#	ARTICLE	IF	CITATIONS
1	Carotid Intima-Media Thickness and Presence or Absence of Plaque Improves Prediction of Coronary Heart Disease Risk. Journal of the American College of Cardiology, 2010, 55, 1600-1607.	2.8	794
2	Cardiac Troponin T Measured by a Highly Sensitive Assay Predicts Coronary Heart Disease, Heart Failure, and Mortality in the Atherosclerosis Risk in Communities Study. Circulation, 2011, 123, 1367-1376.	1.6	655
3	Age- and Sex-Dependent Upper Reference Limits for the High-Sensitivity Cardiac Troponin T Assay. Journal of the American College of Cardiology, 2014, 63, 1441-1448.	2.8	303
4	Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. Lancet Diabetes and Endocrinology, 2016, 4, 840-849.	11.4	159
5	Recommendations for the Assessment of Carotid Arterial Plaque by Ultrasound for the Characterization of Atherosclerosis and Evaluation of Cardiovascular Risk: From the American Society of Echocardiography. Journal of the American Society of Echocardiography, 2020, 33, 917-933.	2.8	156
6	High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study. Circulation, 2019, 139, 2642-2653.	1.6	155
7	Common carotid artery intima-media thickness is as good as carotid intima-media thickness of all carotid artery segments in improving prediction of coronary heart disease risk in the Atherosclerosis Risk in Communities (ARIC) study. European Heart Journal, 2012, 33, 183-190.	2.2	149
8	Obesity and Subtypes of Incident Cardiovascular Disease. Journal of the American Heart Association, 2016, 5, .	3.7	149
9	Troponin T, N-Terminal Pro-B-Type Natriuretic Peptide, and Incidence of Stroke. Stroke, 2013, 44, 961-967.	2.0	145
10	Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease. Journal of the American College of Cardiology, 2018, 72, 156-169.	2.8	124
11	Six-Year Change in High-Sensitivity Cardiac Troponin T and Risk of Subsequent Coronary Heart Disease, Heart Failure, and Death. JAMA Cardiology, 2016, 1, 519.	6.1	109
12	Carotid Arterial Wall Characteristics Are Associated With Incident Ischemic Stroke But Not Coronary Heart Disease in the Atherosclerosis Risk in Communities (ARIC) Study. Stroke, 2012, 43, 103-108.	2.0	103
13	Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide. JAMA Cardiology, 2017, 2, 361.	6.1	88
14	High-Sensitivity Cardiac Troponin T and Risk of Hypertension. Circulation, 2015, 132, 825-833.	1.6	84
15	Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide: A Biomarker Approach to Predict Heart Failure Risk—The Atherosclerosis Risk in Communities Study. Clinical Chemistry, 2013, 59, 1802-1810.	3.2	82
16	Obesity, Subclinical Myocardial Injury, and Incident Heart Failure. JACC: Heart Failure, 2014, 2, 600-607.	4.1	81
17	Lipoprotein-Associated Phospholipase A ₂ and High-Sensitivity C-Reactive Protein Improve the Stratification of Ischemic Stroke Risk in the Atherosclerosis Risk in Communities (ARIC) Study. Stroke, 2009, 40, 376-381.	2.0	79
18	Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality. Annals of Epidemiology, 2013, 23, 66-73.	1.9	72

#	ARTICLE	IF	CITATIONS
19	Combination Therapy with Statins and Omega-3 Fatty Acids. American Journal of Cardiology, 2006, 98, 34-38.	1.6	71
20	Frequency and Practice-Level Variation in Inappropriate Aspirin Use for the Primary Prevention of Cardiovascular Disease. Journal of the American College of Cardiology, 2015, 65, 111-121.	2.8	63
21	Oral Antiplatelet Therapy After Acute Coronary Syndrome. JAMA - Journal of the American Medical Association, 2021, 325, 1545.	7.4	62
22	Provider understanding of the 2013 ACC/AHA cholesterol guideline. Journal of Clinical Lipidology, 2016, 10, 497-504.e4.	1.5	61
23	High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. American Heart Journal, 2015, 169, 31-38.e3.	2.7	59
24	Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition) Tj ETQq0 0 QngBT /Overclock 10 T		
25	Causal Role of Alcohol Consumption in an Improved Lipid Profile: The Atherosclerosis Risk in Communities (ARIC) Study. PLoS ONE, 2016, 11, e0148765.	2.5	57
26	Short-Term Global Cardiovascular Disease Risk Prediction in Older Adults. Journal of the American College of Cardiology, 2018, 71, 2527-2536.	2.8	56
27	Development and Validation of Machine Learning-Based Race-Specific Models to Predict 10-Year Risk of Heart Failure: A Multicohort Analysis. Circulation, 2021, 143, 2370-2383.	1.6	56
28	Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline. Circulation, 2019, 140, 2076-2088.	1.6	49
29	Heart Failure Risk Across the Spectrum of Ankle-Brachial Index. JACC: Heart Failure, 2014, 2, 447-454.	4.1	46
30	Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs. Vascular Medicine, 2018, 23, 232-240.	1.5	46
31	Frequency and Practice-Level Variation in Inappropriate and Nonrecommended Prasugrel Prescribing. Journal of the American College of Cardiology, 2014, 63, 2876-2877.	2.8	44
32	Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study. Atherosclerosis, 2019, 282, 52-56.	0.8	44
33	Statin Use and Its Facility-Level Variation in Patients With Diabetes: Insight From the Veterans Affairs National Database. Clinical Cardiology, 2016, 39, 185-191.	1.8	43
34	BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study. International Journal of Cardiology, 2017, 233, 61-66.	1.7	42
35	Performance of the Pooled Cohort Equations to Estimate Atherosclerotic Cardiovascular Disease Risk by Body Mass Index. JAMA Network Open, 2020, 3, e2023242.	5.9	42
36	Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Peripheral Arterial and Ischemic Cerebrovascular Disease Compared to Veterans With Coronary Heart Disease. American Journal of Cardiology, 2016, 118, 1144-1149.	1.6	39

#	ARTICLE	IF	CITATIONS
37	High-Sensitivity Troponin T and Cardiovascular Events in Systolic Blood Pressure Categories. Hypertension, 2015, 65, 78-84.	2.7	35
38	Prognostic Significance of High-Sensitivity Cardiac Troponin T Concentrations between the Limit of Blank and Limit of Detection in Community-Dwelling Adults: A Metaanalysis. Clinical Chemistry, 2015, 61, 1524-1531.	3.2	34
39	The use of myeloperoxidase as a risk marker for atherosclerosis. Current Atherosclerosis Reports, 2005, 7, 127-131.	4.8	33
40	Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure. Circulation, 2020, 141, 957-967.	1.6	33
41	Temporal Trends in E-Cigarette Use Among U.S. Adults: Behavioral Risk Factor Surveillance System, 2016 to 2018. American Journal of Medicine, 2020, 133, e508-e511.	1.5	31
42	Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events. Journal of the American College of Cardiology, 2021, 77, 559-571.	2.8	31
43	Novel Ultrasound Methods to Investigate Carotid Artery Plaque Vulnerability. Journal of the American Society of Echocardiography, 2017, 30, 139-148.	2.8	30
44	The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study. Atherosclerosis, 2017, 262, 131-137.	0.8	29
45	Troponin in Cardiovascular Disease Prevention: Updates and Future Direction. Current Atherosclerosis Reports, 2016, 18, 12.	4.8	28
46	Determinants of minimal elevation in high-sensitivity cardiac troponin T in the general population. Clinical Biochemistry, 2016, 49, 657-662.	1.9	28
47	Primary Prevention of Atherosclerosis. Journal of the American College of Cardiology, 2017, 70, 2992-2994.	2.8	26
48	Obesity and the paradox of mortality and heart failure hospitalization in heart failure with preserved ejection fraction. International Journal of Obesity, 2020, 44, 1561-1567.	3.4	26
49	Diagnosis and Management of Pulmonary Hypertension in Patients With CKD. American Journal of Kidney Diseases, 2020, 75, 935-945.	1.9	25
50	Associations of High-Sensitivity Troponin and Natriuretic Peptide Levels With Outcomes After Intensive Blood Pressure Lowering. JAMA Cardiology, 2021, 6, 1397.	6.1	24
51	Integration of cardiovascular risk assessment with COVID-19 using artificial intelligence. Reviews in Cardiovascular Medicine, 2020, 21, 541.	1.4	24
52	Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry. Journal of the American Heart Association, 2018, 7, .	3.7	23
53	Zero Coronary Artery Calcium Score. Circulation, 2020, 142, 917-919.	1.6	23
54	High Burden of Subclinical and Cardiovascular Disease Risk in Adults With Metabolically Healthy Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care, 2021, 44, 1657-1663.	8.6	22

#	ARTICLE	IF	CITATIONS
55	Determinants of Incident Atherosclerotic Cardiovascular Disease Events Among Those With Absent Coronary Artery Calcium: Multi-Ethnic Study of Atherosclerosis. <i>Circulation</i> , 2022, 145, 259-267.	1.6	21
56	Physical Activity, Obesity, and Subclinical Myocardial Damage. <i>JACC: Heart Failure</i> , 2017, 5, 377-384.	4.1	20
57	Associations Between Carotid Artery Plaque Burden, Plaque Characteristics, and Cardiovascular Events. <i>JAMA Cardiology</i> , 2021, 6, 79-86.	6.1	20
58	Myocardial Injury, Obesity, and the Obesity Paradox. <i>JACC: Heart Failure</i> , 2017, 5, 56-63.	4.1	19
59	ApoB, small-dense LDL-C, Lp(a), LpPLA ₂ activity, and cognitive change. <i>Neurology</i> , 2019, 92, e2580-e2593.	1.1	19
60	Plasma Dehydroepiandrosterone Sulfate and Cardiovascular Disease Risk in Older Men and Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4304-e4327.	3.6	19
61	E-cigarette Use and Risk Behaviors among Lesbian, Gay, Bisexual, and Transgender Adults: The Behavioral Risk Factor Surveillance System (BRFSS) Survey. <i>Kansas Journal of Medicine</i> , 2020, 13, 318-321.	0.4	18
62	Carotid intima-media thickness and cardiovascular events. <i>Lancet</i> , The, 2012, 379, 2028-2030.	13.7	17
63	Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline. <i>Atherosclerosis</i> , 2016, 246, 115-120.	0.8	17
64	Association between high-sensitivity troponin T and cardiovascular risk in individuals with and without metabolic syndrome: The ARIC study. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 628-638.	1.8	17
65	Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial. <i>Circulation</i> , 2019, 139, 1341-1343.	1.6	17
66	Lipoprotein-associated phospholipase A2: Pathogenic mechanisms and clinical utility for predicting cardiovascular events. <i>Current Atherosclerosis Reports</i> , 2006, 8, 374-381.	4.8	16
67	Postprandial lipemia and the risk of coronary heart disease and stroke: the Atherosclerosis Risk in Communities (ARIC) Study. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000335.	2.8	16
68	Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System. <i>American Journal of Medicine</i> , 2019, 132, e693-e700.	1.5	16
69	Association of Body Mass Index and Waist Circumference with Subclinical Atherosclerosis in Retired NFL Players. <i>Southern Medical Journal</i> , 2014, 107, 633-639.	0.7	16
70	Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study. <i>Atherosclerosis</i> , 2016, 253, 156-163.	0.8	15
71	Levels and Change in Galectin-3 and Association With Cardiovascular Events: The ARIC Study. <i>Journal of the American Heart Association</i> , 2020, 9, e015405.	3.7	15
72	Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e53-e64.	1.8	15

#	ARTICLE	IF	CITATIONS
73	Upper Reference Limits for High-Sensitivity Cardiac Troponin T and N-Terminal Fragment of the Prohormone Brain Natriuretic Peptide in Patients With CKD. American Journal of Kidney Diseases, 2022, 79, 383-392.	1.9	15
74	Role of Biomarkers in Developing New Therapies for Vascular Disease. World Journal of Surgery, 2007, 31, 676-681.	1.6	14
75	The 9p21 genetic variant is additive to carotid intima media thickness and plaque in improving coronary heart disease risk prediction in white participants of the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis, 2012, 222, 135-137.	0.8	14
76	Calf muscle perfusion as measured with magnetic resonance imaging to assess peripheral arterial disease. Medical and Biological Engineering and Computing, 2016, 54, 1667-1681.	2.8	14
77	Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Tj ETQq1 1 0,784314 rgBT /Overdo	1.6	14
78	Differences in responses of platelets to fluid shear stress in patients with peripheral artery disease (PAD) and coronary artery disease (CAD). Platelets, 2009, 20, 199-205.	2.3	13
79	Carotid Intimaâ€Media Thickness and the Risk of Sudden Cardiac Death: The ARIC Study and the CHS. Journal of the American Heart Association, 2020, 9, e016981.	3.7	13
80	Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation, 2019, 139, 410-412.	1.6	12
81	LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Journal of Lipid Research, 2012, 53, 556-560.	4.2	11
82	Relation Between Playing Position and Coronary Artery Calcium Scores in Retired National Football League Players. American Journal of Cardiology, 2014, 114, 1836-1840.	1.6	11
83	Cardiovascular Disease Prevention: Training Opportunities, the Challenges, and Future Directions. Current Atherosclerosis Reports, 2018, 20, 35.	4.8	11
84	Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria. American Journal of Medicine, 2015, 128, 1253-1256.	1.5	10
85	Postprandial effects on arterial stiffness parameters in healthy young adults. Vascular Medicine, 2015, 20, 501-508.	1.5	10
86	Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse. Journal of Clinical Lipidology, 2018, 12, 1141-1145.	1.5	10
87	Association of PCSK9 Variants With the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy. Current Problems in Cardiology, 2022, 47, 101043.	2.4	10
88	Heart Failure Risk Associated With Severity of Modifiable Heart Failure Risk Factors: The ARIC Study. Journal of the American Heart Association, 2022, 11, e021583.	3.7	10
89	Distribution of calcification in carotid endarterectomy tissues: Comparison of micro-computed tomography imaging with histology. Vascular Medicine, 2014, 19, 343-350.	1.5	9
90	Inclisiran. Journal of the American College of Cardiology, 2021, 77, 1194-1196.	2.8	9

#	ARTICLE	IF	CITATIONS
91	Association Between Omega-3 Fatty Acid Treatment and Atrial Fibrillation in Cardiovascular Outcome Trials: A Systematic Review and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 793-800.	2.6	9
92	Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) guidelines for management of dyslipidemia and cardiovascular disease risk reduction: Putting evidence in context. <i>Progress in Cardiovascular Diseases</i> , 2021, 68, 2-6.	3.1	9
93	Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players. <i>Atherosclerosis</i> , 2014, 236, 251-256.	0.8	8
94	Trends in Blood Pressure and High-Sensitivity Cardiac Troponin-T With Cardiovascular Disease: The Cardiovascular Health Study. <i>American Journal of Hypertension</i> , 2019, 32, 1013-1020.	2.0	8
95	Soluble Angiotensin-Converting Enzyme 2, Cardiac Biomarkers, Structure, and Function, and Cardiovascular Events (from the Atherosclerosis Risk in Communities Study). <i>American Journal of Cardiology</i> , 2021, 146, 15-21.	1.6	8
96	Obesity, Galectin-3, and Incident Heart Failure: The ARIC Study. <i>Journal of the American Heart Association</i> , 2022, 11, e023238.	3.7	8
97	Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk. <i>Current Atherosclerosis Reports</i> , 2005, 7, 22-28.	4.8	7
98	High-Sensitive Troponin T, Natriuretic Peptide, and Cognitive Change. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 2353-2361.	2.6	7
99	Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH). <i>Journal of Clinical Lipidology</i> , 2021, 15, 649-652.	1.5	7
100	Carotid Plaque or CIMT: What is the Future for Carotid US Imaging?. <i>Current Cardiovascular Risk Reports</i> , 2014, 8, 1.	2.0	6
101	A dataset to assess providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline. <i>Data in Brief</i> , 2016, 7, 595-598.	1.0	6
102	Magnetic Resonance Venous Volume Measurements in Peripheral Artery Disease (from ELIMIT). <i>American Journal of Cardiology</i> , 2016, 118, 1399-1404.	1.6	6
103	A simplified pathway to proprotein convertase subtilisin/kexin type 9 inhibitor prior authorization approval: A lipid clinic experience. <i>Journal of Clinical Lipidology</i> , 2017, 11, 596-599.	1.5	6
104	Matrix metalloproteinase-1 and tissue inhibitors do not predict incident coronary artery disease in the atherosclerosis risk in communities (ARIC) study. <i>Texas Heart Institute Journal</i> , 2008, 35, 388-94.	0.3	6
105	The impact of multiple single day blood pressure readings on cardiovascular risk estimation: The Atherosclerosis Risk in Communities study. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1529-1536.	1.8	5
106	Effectiveness of Percutaneous Intervention for Patients With Obstructive Hypertrophic Cardiomyopathy and Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2005, 96, 580-581.	1.6	4
107	Relation of Magnetic Resonance Imaging Based Arterial Signal Enhancement to Markers of Peripheral Artery Disease. <i>American Journal of Cardiology</i> , 2021, 140, 140-147.	1.6	4
108	Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the Veteran's Affairs healthcare system. <i>Journal of Clinical Lipidology</i> , 2021, 15, 832-839.	1.5	4

#	ARTICLE	IF	CITATIONS
109	Response by Jia et al to Letter Regarding Article, “High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study” Circulation, 2019, 140, e772-e773.	1.6	3
110	Association between circulating Galectin-3 and arterial stiffness in older adults. Vasa - European Journal of Vascular Medicine, 2021, 50, 439-445.	1.4	3
111	Associations of High-Sensitivity Troponin and Natriuretic Peptide Levels With Serious Adverse Events in SPRINT. Journal of the American Heart Association, 2022, 11, e023314.	3.7	3
112	Midlife determinants of healthy cardiovascular aging: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis, 2022, 350, 82-89.	0.8	3
113	Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor. JACC: Case Reports, 2020, 2, 1042-1045.	0.6	2
114	ASCOT-LLA and the primary prevention of coronary artery disease in hypertensive patients. Current Atherosclerosis Reports, 2004, 6, 353-358.	4.8	1
115	Understanding by General Providers of the Echocardiogram Report. American Journal of Cardiology, 2019, 124, 296-302.	1.6	1
116	Letter to the Editor: Temporal Trends in E-Cigarette and Cigarette Use Among US Adults by US State: Behavioral Risk Factor Surveillance System, 2016 to 2018. Population Health Management, 2021, 24, 414-415.	1.7	1
117	Statins and Your Memory. Journal of the American College of Cardiology, 2021, 77, 3157-3159.	2.8	1
118	“Sound Advice” Let’s “Stress” the Importance of Prevention: Combining Carotid Ultrasound and Stress Echocardiography for Cardiovascular Risk Assessment. Journal of the American Society of Echocardiography, 2020, 33, 570-572.	2.8	1
119	Abstract 138: Contemporary Patterns of Use of Antiplatelet Agents in Patients With Acute Myocardial Infarction: Insight From the National Cardiovascular Data Registry (NCDR). Circulation: Cardiovascular Quality and Outcomes, 2016, 9, .	2.2	1
120	Abstract 4985: Are All Patients Considered “Low Risk” for Coronary Heart Disease Really Low Risk? An Analysis from the Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2008, 118, .	1.6	1
121	Abstract 020: NT-proBNP, hs-Troponin T and Incident Venous Thromboembolism: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2013, 127, .	1.6	1
122	Newer Markers for Population Screening: Focus on Lipoprotein-Related Markers. , 0, , 181-203.		0
123	Carotid Intima Media Thickness Versus Carotid Plaque in Cardiovascular Risk Evaluation. Current Cardiovascular Risk Reports, 2011, 5, 149-158.	2.0	0
124	Risk Statins or Risk “Zero” on Atherosclerosis Imaging for Risk Stratification? —. Journal of the American College of Cardiology, 2016, 68, 892-894.	2.8	0
125	Seven Metrics That Will Determine Your Cardiovascular Success or Failure. JACC: Heart Failure, 2019, 7, 648-650.	4.1	0
126	Is There an Optimal Antiplatelet Strategy after Gastrointestinal Bleeding in Patients with Coronary Artery Disease?. Cardiology, 2021, 146, 668-677.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Abstract MP074: High-sensitivity C-reactive Protein and Family History in the Prediction of Risk for Coronary Heart Disease: The Atherosclerosis Risk in Communities Study. Circulation, 2012, 125, .	1.6	0
128	Abstract 303: Pre-operative Angiotensin Converting Enzyme Inhibitor use and outcomes in patients undergoing Isolated Coronary Artery Bypass Grafting. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, .	2.2	0
129	Abstract 304: The Outcomes of Pre-Procedural Angiotensin Converting Enzyme Inhibitor Therapy in patients undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, .	2.2	0
130	Abstract 453: Ceruloplasmin and Cardiovascular Disease in the Atherosclerosis Risk in Communities (ARIC) Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, .	2.4	0
131	Abstract 79: Troponin T, NT-proBNP, and Incidence of Stroke: The Atherosclerosis Risk in Communities (ARIC) Study. Stroke, 2013, 44, .	2.0	0
132	Abstract P050: Glycated Hemoglobin Versus Fasting Glucose in Defining Metabolic Syndrome and Prediction of Coronary Heart Disease. Circulation, 2013, 127, .	1.6	0
133	Abstract MP27: Cardiovascular Biomarkers and MRI-defined Small Vessel Disease of the Brain in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2013, 127, .	1.6	0
134	Abstract P385: Arterial Stiffness and Contralateral Differences in Ankle Blood Pressure: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2013, 127, .	1.6	0
135	Abstract MP75: Glycemia (Hemoglobin A1c) is Not Related to Incident Venous Thromboembolism in the Atherosclerosis Risk in Communities Study. Circulation, 2013, 127, .	1.6	0
136	Abstract 18: The Effect of Lipid Modification on Peripheral Arterial Disease after Endovascular Intervention Trial (ELIMIT). Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, .	2.4	0
137	Abstract P010: Cardiac Risk Factors and 6-Year Change in high-sensitivity Cardiac Troponin-T.. Circulation, 2014, 129, .	1.6	0
138	Abstract 15: Frequency and Predictors of Inappropriate Aspirin Prescribing for Primary Prevention of Cardiovascular Disease: Insights from the NCDRA® PINNACLE Registry.. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, .	2.2	0
139	Abstract 19852: The Relationship Between Obesity and Heart Failure is Stronger than Those for Other CVD Subtypes and Not Explained by Traditional Risk Factors. Circulation, 2014, 130, .	1.6	0
140	Abstract P244: Combined Measures of Total and Abdominal Adiposity and the Likelihood of Subclinical Myocardial Damage. Circulation, 2015, 131, .	1.6	0
141	Abstract 18914: Comparison of Statin Eligibility Using the Pooled Cohort Equations, ATP-III Framingham and Reynolds Risk Scores Among Adults Who Experienced ASCVD Events: The Atherosclerosis Risk in Communities Study. Circulation, 2015, 132, .	1.6	0
142	Abstract 14: Statin Use Before and After the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, .	2.2	0
143	Abstract 008: Statin Use and Its Facility Level Variation in Patients With Peripheral Artery Disease: Insights From the Department of Veterans Affairs. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	0
144	Abstract 195: Statin Use and Its Facility Level Variation in Patients With Ischemic Cerebrovascular Disease: Insights From the Department of Veterans Affairs. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	0

#	ARTICLE	IF	CITATIONS
145	Abstract 193: Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglyceride and Incident Cardiovascular Disease in the Atherosclerosis Risk in Communities Study: Can Genetic Variants Provide New Insights on Triglycerides and Atherogenic Lipoproteins?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, .	2.4	0
146	Abstract P168: The Association of Longitudinal Changes in Metabolic Syndrome With Incident Heart Failure: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2018, 137, .	1.6	0
147	Abstract 17187: The Association of Longitudinal Patterns of Metabolic Syndrome With Elevated hs-cTnT: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2018, 138, .	1.6	0
148	Abstract P036: Association Between Circulating Galectin-3 and Arterial Stiffness in the Atherosclerosis Risk in Communities Study. Circulation, 2019, 139, .	1.6	0
149	SUN-541 Effect of Testosterone Replacement Therapy Added to Intensive Lifestyle Intervention in Frail, Older Male Veterans with Hypogonadism and Obesity: A Randomized Clinical Trial. Journal of the Endocrine Society, 2020, 4, .	0.2	0
150	Safety of Evolocumab in People Living With HIV Infection. Journal of the American College of Cardiology, 2020, 75, 2585-2587.	2.8	0
151	Abstract 15216: Longitudinal Changes in Peak Aortic Valve Velocity in Late Life: Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2020, 142, .	1.6	0
152	Abstract 16063: Demographic Differences in the Burden of Heart Failure Attributable to Obesity-Associated Metabolic Risk Factors: The Atherosclerosis in Communities (ARIC) Study. Circulation, 2020, 142, .	1.6	0
153	Abstract 14594: Association Between Life's Simple 7 and Cardiovascular Disease in Cancer Patients Compared to Noncancer Controls in the Aric Cohort. Circulation, 2020, 142, .	1.6	0
154	Response to Azarpazhooh et al. Reliability, reproducibility and advantages of measuring carotid total plaque area. Journal of the American Society of Echocardiography, 2022, , .	2.8	0
155	Abstract P064: Metabolic Risk Transitions In Obesity With The Incidence Of Heart Failure And Coronary Heart Disease: The Atherosclerosis Risk In Communities (aric) Study. Circulation, 2022, 145, .	1.6	0
156	Abstract P109: Association Of The 2017 ACC/AHA Blood Pressure Guideline With Blood Pressure Change In Community-dwelling Older Adults Between 2016-2019: A Difference-in-differences Analysis In The ARIC Study. Circulation, 2022, 145, .	1.6	0
157	Abstract 88: The effect of statins on incidence of infections after Coronary Artery Bypass Grafting. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, .	2.2	0
158	Abstract 19227: Weight History Influences the Likelihood of Subclinical Myocardial Injury. Circulation, 2015, 132, .	1.6	0
159	Abstract 16254: Heart Rate as a Prognostic Marker in Patients With Heart Failure With Preserved Ejection Fraction. Circulation, 2015, 132, .	1.6	0